David R. Spigel, MD, FASCO
@davidrspigel
Chief Scientific Officer at Sarah Cannon Research Institute | Advancing Therapies Through Clinical Research #Oncology #Healthcare #CancerResearch
ID: 260571752
https://www.scri.com/ 04-03-2011 04:03:35
61 Tweet
2,2K Followers
486 Following
Way to go Joshua Sabari, MD! #LCSM
Thank you Mandy Davis Aitken ! You and your team are amazing and make the meeting such a great experience.
The triplet with Cabozantinib Nivolumab and Ipilimumab may not be the new standard. But I commend the study for a modern control arm. Perhaps another triplet may bring further benefit to our patients. More work to be done and Sarah Cannon Docs will help.
The SCRI annual meeting has been a great time to connect with colleagues across the country. Excited to talk about how we move gu oncology research forward. Special shout out to Mike Lattanzi who I may call on and the other GU physicians in our network. Sarah Cannon Docs
LCRF has announced 3 research grant awards funded by Daiichi Sankyo and AstraZeneca, focused on further developing the understanding of the proposed mechanism of action of antibody drug conjugates (ADCs). LCRF.org/ADC #LungCancer Aakash Desai, MD, MPH nan.sethakorn Carl Gay, MD, PhD
LCRF announces its 9/24 Evening of Innovation gala honoree, Dr. Mark G. Kris of Memorial Sloan Kettering Cancer Center. Dr. Kris exemplifies the spirit of LCRF to improve the lives of those with #LungCancer through research. Read about this tireless visionary & advocate: LCRF.org/gala-article
Dr. Meredith McKean MD, MPH has exciting news for BRAF-mutant cancers and will discuss the Phase 1 trial of PF-07799933 (ARRY-440), a next-generation BRAF inhibitor, today. Stay tuned for more insights. #BRAFmutation #AACR24
SCRI Research Leader Haydar Frangoul helped pioneer exciting research published today in NEJM showing results of CRISPR/Cas9 gene-editing therapy for the treatment of #SickleCellDisease. Read more: nejm.org/doi/full/10.10… TriStar Health
…but that’s not all! Dr. Haydar Frangoul also contributed to research published today in The New England Journal of Medicine showing the encouraging results of CRISPR/Cas9 gene-editing therapy for the treatment of Transfusion-Dependent Beta Thalassemia. nejm.org/doi/full/10.10…
🚨🥁HOT OFF THE PRESS👉Just in time for ASCO #ASCO24 published in the highest impact factor journal in all of oncology CA: A Cancer Journal for Clinicians American Cancer Society CA: A Cancer Journal for Clinicians 👉Such a delight to share with the world in open access for all to read 💥The evolving
In today’s #ASCO24 Opening Session, Skip Burris, MD’s message was clear: Research Conquers Cancer. We echo his gratitude towards our oncology researchers’ unwavering commitment to patients everywhere. 👏👏👏 #oncologyresearch
Terrific ASCO #ASCO24 with thoracic 🫁 friends! Waiting to see many more tonight IASLC reception! Karen Kelly Heather Wakelee Suresh S. Ramalingam, MD, FASCO David R. Spigel, MD, FASCO Jarushka Naidoo Jhanelle Gray MD Melina Marmarelis Lova Sun Luis E Raez Edgardo S. Santos, M.D., FACP, FASCO Ben Solomon A/Prof Tom John Lecia Sequist, MD, MPH
.Lecia Sequist, MD, MPH eloquently discusses LAURA. Acknowledges EGFR M+ st 3 is likely incurable according to this data. Indefinite Rx is an issue but need to identify pts suitable for de-escalation. This data supports TKI in other AGA with CNS penetrating TKIs. #ASCO24
Great discussion of IO in SCLC by Lauren Averett Byers, MD ASCO after presentation of ADRIATIC consolidation durvalumab after chemoXRT in LS-SCLC by David R. Spigel, MD, FASCO #MedIQASCO2024
